HomeBUSINESS
BUSINESS

Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
(Nov.28.2017)

AstraZeneca filed an application in Japan on November 27 seeking regulatory clearance for the front-line use of its EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in patients with inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)